BioSpace News Archive

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has received United States Patent No. 10,920,274 entitled “Nucleic Acid Coated Submicron Particles for Authentication” from the United States Patent and Trademark Office.

CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice from Lung Biotechnology, a United Therapeutics subsidiary

Stella Diagnostics, Inc . today announced that it has appointed Peter A. Cohen, Seth Platt, and David Seaburg to its Board of Directors. The three new members have decades of experience in asset management, investment banking and corporate development - having held various executive roles for multiple leading, global institutions.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. (“RedChip”) to lead its investor relations efforts.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after the market closes.

The University of California, San Francisco (UCSF) and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS)

By 2024, the North America molecular diagnostics market share is slated to surpass USD 5.3 billion annually.

Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, is pleased to join national and international efforts to raise awareness about rare diseases and their impact on patients’ lives this Rare Disease Day, February 28.

Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy® Business Unit as well as the appointment of Mike Doherty as Sr. Strategy

In a new study released today by the EveryLife Foundation for Rare Diseases, the estimated economic cost of 379 rare diseases in the United States totaled $966 billion in 2019, a figure that surpasses the economic burden estimated for many of the costliest chronic diseases described by the Centers for Disease Control and Prevention (CDC), including diabetes, heart disease, and cancer.